

# Unlocking patient-level data at scale with federated computing to drive collaborative research and advance science

NVIDIA FLARE Event 2024

Eric Boernert,  
Product Manager Federated Open Science, Roche Informatics

# Today's speakers



**Eric Boernert**

Product Manager, Federated Open Science



**Jacek Chmiel**

Product Expert, Federated Open Science



**Fahime Sheikhzadeh**

Principal Imaging Scientist, Digital Pathology

# Roche at a glance

Who we are and what we do



**128 years**

founded in Basel in 1896



**A leader in  
healthcare R&D**

with CHF 13.2 billion invested  
in 2023



**3 Nobel prizes and  
44 Prix Galien**

since 1974



**CHF 58.7 billion\***

in Roche Group sales in 2023



**45 Roche medicines  
& 90 diagnostics\*\***

on the WHO List of  
Essential Medicines & Tests



**>100,000**

dedicated employees  
worldwide



**>22 million people**

treated with our medicines  
in 2023



**29 billion tests**

conducted with our  
Diagnostics products in 2023

\*Unless otherwise stated, all growth rates and comparisons to the previous year are at constant exchange rates (CER; average rates 2023) and all total figures quoted are reported in CHF.

\*\* Medicines and tests that have either been developed or acquired by Roche

# Introduction

*Making data Findable, Accessible,  
Interoperable, Reusable (FAIR)*

*Deep, longitudinal data from  
broad patient populations*

*Moving the analytics/algorithm to the data while preserving  
privacy instead of moving the data to the analytics/algorithm*

**Unlocking patient-level data at scale with federated computing to drive collaborative research and advance science**


*Individual data separately recorded for each participant in  
a clinical study or in routine clinical practice*

*Building trust and bringing together researchers to  
generate new data-driven insights*

# Federated Open Science

#InvestingInTechForTomorrow

- Our focus is on next-generation and fit-for-purpose federation technology capability development and adoption for **real world healthcare settings** to:
  - Enable trusted and sustainable data collaborations among various stakeholders and across institutional/national borders
  - Increase data sovereignty for secure and data owner controlled access to meaningful, high-quality, multimodal and diverse patient-level RWD for secondary research purposes



# Collaborative spirit in action

Strategic thought partnership

- [Preventing Health Data Leaks with Federated Learning Using NVIDIA FLARE](#) - creating networks of trust supported by technology (unsafe jobs vs. safe jobs)
- Resilience and debuggability of NVFlare solutions
- New messaging backend
- Federated XGBoost
- Homomorphic Encryption
- Differential Privacy + privacy meters
- Confidential Computing
- Federated LLMs support
- New data scientist experience feedback incl. ML to FL transition
- Integration with Flower
- ... and many more

Two-way exchange of design ideas


Valuable help and guidance

Enterprise viewpoint  
→ meaningful feedback

Enthusiastic atmosphere with  
focus on moving forward

# Use Case I

A Real-world Pilot Study with Roche Diagnostics Solutions, University Hospital Zurich & University of Zurich




✓ Established Federated Learning Pipeline between Roche and USZ across different continents, using NVIDIA FLARE

The first ever real-world FL Pipeline involving Roche as a partner

# Federated model learned data insights as effectively as centralized model

## Centralized Model


TuPro Train All Dataset



Server



CL Model




**Test Score (TuPro Test Dataset)**

Segmentation: **0.82**

Cell Detection: **0.77**



## Federated Model

TuPro Train Dataset 1




USZ Client

TuPro Train Dataset 2




LeoMed Client

TuPro Train Dataset 3



Roche Client



Server



FL Model



**Test Score (TuPro Test Dataset)**

Segmentation: **0.78**


Cell Detection: **0.78**



**FL ~ CL**



# Federated model gained new insights from new client data sets which Roche has no access



✓ The FL model achieved better or equivalent performance across all three client test sets!

# Use Case I

## Conclusions

FL model achieves equal or better performance compared to the centralized model.

FL model generalizes better than the centralized model across clients

### Challenges:



- Experiment duration
- Manual intervention (“babysitting”) required
- Each client site requires interdisciplinary team (algorithm design, medical and IT infrastructure expertise)

### Learnings:



- Real-world FL is possible, but challenging and relies on an interdisciplinary team!
- Optimize experiment duration first
- Investigate model performance on client datasets for guidance on domain alignment

# Use Case II

INTONATE-MS academia-industry collaborative federated research network

- Innovative discoveries in chronic neurological diseases – collaborations in partnership
  - Heinz Wiendl, Univ.-Prof. Dr. med: ....*An innovative and visionary initiative in the area of academic (public) industry collaborations with a potential to revolutionise our usage and understanding of clinical and research data, biosamples and their respective analyses in neuroscience...*<sup>1</sup>
- Situation in Multiple sclerosis (MS)
  - MS is a disease of the central nervous system, estimated to affect 2.3 million people worldwide<sup>2</sup>
  - MS is a condition that has a great degree of variability across people and across time
  - There is no cure for MS yet and research continues to better understand and treat the disease
- Big data & Machine Learning in MS
  - Overcoming the complexity of the disease and its treatment, specifically in addressing challenging topics such as diagnosis, progression and personalized treatments
  - Heterogeneous disease course requires large-scale quality datasets incl. combining real-world with clinical trial data

# Use Case II

From pathfinding to scaling

- Federated study 1
  - Enhance understanding and utility about novel concepts such as lack of disease stability in clinical practice and for new biomarker development
  - Applying a Federated Analysis on a combined cohort from real-world clinical settings and clinical trials
- Federated study 2
  - Towards automated and data-driven MRI analyses for monitoring disease and progression
  - i.a. Evaluating a high-precision brain lesion segmentation algorithm against real-world imaging data
- Federated study 3
  - Exploring the clinical and social-economic benefits of high treatment persistence in an international setting
  - Model development and validation investigating statistical inference in presence of heterogeneity in data distributions across sites
- Federated study 4
  - Explore the incidence of silent disease progression in a multi-center, multi-country, retrospective study
  - Overcoming limited patient pool challenge in MS and establishing faster, cheaper and sustainable access to a large-scale, heterogeneous and longitudinal patient cohort

# Use Case III

EU IHI IDERHA

## IDERHA Vision

*Integration of heterogenous Data and Evidence towards Regulatory & HTA Acceptance*


'In IDERHA we will be an open, disease agnostic, federated data space which enables connectivity, access, use and reuse of digital health data, and develop consensus policy recommendations on health data access and heterogeneous health research (e.g. RWE) for regulatory and HTA decision-making.'



[www.iderha.org](http://www.iderha.org)



[www.linkedin.com/company/iderha](https://www.linkedin.com/company/iderha)



[www.IDERHA.org](http://www.IDERHA.org)



# Acknowledgements

Bartłomiej Szubstarski, Lukasz Antczak, Jacek Chmiel, Paulina Kaminska, Lukasz Kaczmarek, Mariusz Majcher, Karol Kaliszczak, Kamil Filochowski, Marcela Dobrzynska, Gabriele Zilorri, Tomasz Kubicz, Yuri Pyatkin, Shauna Gysin, Joerg Menner, Michael Strumpf, Luca La Porta, Heike Prior, Dominik Heinzmann, Joel Federer-Gsponer, Frederik Buijs, Jens Wuerfel, Matthias Antonin, Jan Wesiack, Ramon Aguiar Escobar, Björn Tackenberg, Yao Nie, Ruben Bagan, Arash Moayyedi, Jacob Reimers, Michael Zhou, Kamil Wasaga, Prof. Viktor H. Koelzer, Marta Nowak, Lydia Schönpflug

**Doing now what patients need next**